179 related articles for article (PubMed ID: 12704389)
41. Compliance with oral chemotherapy in childhood lymphoblastic leukaemia.
Davies HA; Lilleyman JS
Cancer Treat Rev; 1995 Mar; 21(2):93-103. PubMed ID: 7758006
[No Abstract] [Full Text] [Related]
42. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
[TBL] [Abstract][Full Text] [Related]
43. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia.
Gale RP; Butturini A
Lancet; 1991 Nov; 338(8778):1315-8. PubMed ID: 1682696
[TBL] [Abstract][Full Text] [Related]
44. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
[TBL] [Abstract][Full Text] [Related]
45. Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival.
Rivard GE; Infante-Rivard C; Dresse MF; Leclerc JM; Champagne J
Chronobiol Int; 1993 Jun; 10(3):201-4. PubMed ID: 8319318
[TBL] [Abstract][Full Text] [Related]
46. Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.
Jung M; Schieck M; Hofmann W; Tauscher M; Lentes J; Bergmann A; Stelter M; Möricke A; Alten J; Schlegelberger B; Schrappe M; Zimmermann M; Stanulla M; Cario G; Steinemann D
Genes Chromosomes Cancer; 2020 Nov; 59(11):667-671. PubMed ID: 32592278
[TBL] [Abstract][Full Text] [Related]
47. Integrative computational in-depth analysis of dysregulated miRNA-mRNA interactions in drug-resistant pediatric acute lymphoblastic leukemia cells: an attempt to obtain new potential gene-miRNA pathways involved in response to treatment.
Mesrian Tanha H; Mojtabavi Naeini M; Rahgozar S; Moafi A; Honardoost MA
Tumour Biol; 2016 Jun; 37(6):7861-72. PubMed ID: 26700663
[TBL] [Abstract][Full Text] [Related]
48. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
49. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
[TBL] [Abstract][Full Text] [Related]
50. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
Ravandi F; Cortes J; Estrov Z; Thomas D; Giles FJ; Huh YO; Pierce S; O'Brien S; Faderl S; Kantarjian HM
Leuk Res; 2002 Jul; 26(7):643-9. PubMed ID: 12008081
[TBL] [Abstract][Full Text] [Related]
51. Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
Jaramillo AC; Cloos J; Lemos C; Stam RW; Kaspers GJL; Jansen G; Peters GJ
Leuk Res; 2019 Apr; 79():45-51. PubMed ID: 30849662
[TBL] [Abstract][Full Text] [Related]
52. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
Nowak D; Liem NL; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP
Exp Hematol; 2015 Jan; 43(1):32-43.e1-35. PubMed ID: 25450514
[TBL] [Abstract][Full Text] [Related]
53. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up.
Freeman AI; Boyett JM; Glicksman AS; Brecher ML; Leventhal BG; Sinks LF; Holland JF
Med Pediatr Oncol; 1997 Feb; 28(2):98-107. PubMed ID: 8986145
[TBL] [Abstract][Full Text] [Related]
54. p16 inactivation associated with aggressive clinical course and fatal outcome in TEL/AML1-positive acute lymphoblastic leukemia.
Papadhimitriou SI; Polychronopoulou S; Tsakiridou AA; Androutsos G; Paterakis GS; Athanassiadou F
J Pediatr Hematol Oncol; 2005 Dec; 27(12):675-7. PubMed ID: 16344676
[TBL] [Abstract][Full Text] [Related]
55. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia.
Schmidt S; Rainer J; Riml S; Ploner C; Jesacher S; Achmüller C; Presul E; Skvortsov S; Crazzolara R; Fiegl M; Raivio T; Jänne OA; Geley S; Meister B; Kofler R
Blood; 2006 Mar; 107(5):2061-9. PubMed ID: 16293608
[TBL] [Abstract][Full Text] [Related]
56. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
Schmiegelow K; Ifversen M
Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
[TBL] [Abstract][Full Text] [Related]
57. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.
Cario G; Stanulla M; Fine BM; Teuffel O; Neuhoff NV; Schrauder A; Flohr T; Schäfer BW; Bartram CR; Welte K; Schlegelberger B; Schrappe M
Blood; 2005 Jan; 105(2):821-6. PubMed ID: 15388585
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells.
Hulleman E; Kazemier KM; Holleman A; VanderWeele DJ; Rudin CM; Broekhuis MJ; Evans WE; Pieters R; Den Boer ML
Blood; 2009 Feb; 113(9):2014-21. PubMed ID: 18978206
[TBL] [Abstract][Full Text] [Related]
59. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium.
Silverman LB; McLean TW; Gelber RD; Donnelly MJ; Gilliland DG; Tarbell NJ; Sallan SE
Cancer; 1997 Dec; 80(12):2285-95. PubMed ID: 9404706
[TBL] [Abstract][Full Text] [Related]
60. Erythroblastic islands.
Astwood E; Vora A
Blood; 2011 Jan; 117(1):10. PubMed ID: 21265064
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
